Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to

Indication
Generalized Myasthenia Gravis

Other upcoming events for VOR

Phase 3 ReadoutPhase 3 Topline: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study With an Open-label Extension Period to — VOR Phase 3 Readout | BioSniper